TransMedics Group, Inc. (TMDX) Interest Coverage Ratio: 7.88x
The interest coverage ratio for TransMedics Group, Inc. (TMDX) is 7.88x as of Saturday, June 20, 2026.
TMDX Interest Coverage Ratio Metrics
INTEREST COVERAGE RATIO
7.88x
TMDX Competitors' Interest Coverage Ratio
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.72B | 7.88x | N/A | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.07B | 2.86x | 2.86x | 2.86x | 6.42x |
| 23andMe Holding Co. (ME)vs › | $15.31M | N/A | N/A | N/A | N/A |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.64B | 5.52x | 5.51x | 7.63x | 62.06x |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | N/A | N/A | N/A | N/A |
| Tempus AI, Inc. (TEM)vs › | $8.87B | -3.40x | N/A | N/A | N/A |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | 4.74x | 3.27x | 5.51x | 5.84x |
| Baxter International Inc. (BAX)vs › | $10.27B | -1.06x | 0.71x | 2.65x | 6.89x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -29.20x | 3.03x | 3.75x | 5.52x |
| Revvity, Inc. (RVTY)vs › | $11.16B | 3.87x | 4.06x | 4.92x | 8.88x |
Financial Health Indicators
Interest Coverage
7.9x
Debt/Equity
0.99
Current Ratio
7.14
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
- < 1.5x: EBIT is less than 1.5 times interest expense
- 1.5x - 3x: EBIT is between 1.5 and 3 times interest expense
- 3x - 5x: EBIT is between 3 and 5 times interest expense
- > 5x: EBIT is more than 5 times interest expense
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
TransMedics Group, Inc. Interest Coverage Ratio Formula & Definition
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
TransMedics Group, Inc. Interest Coverage Ratio FAQ
- What is the interest coverage ratio for TransMedics Group, Inc. (TMDX)?
- The interest coverage ratio for TMDX stock is 7.88x.
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein